In January 2018, researchers at the University of California, Berkeley, announced that they had developed a “toxic” compound to treat rare blood cancers.
But now, they’re asking whether that compound could also be used to combat a deadly disease known as non-Hodgkin lymphoma.
The compound, called pepstatin, has a low affinity for human cells.
It binds to a protein called PEG protein and kills it.
The resulting tumor cells can’t grow back.
And because the compound’s toxicity is extremely low, there’s no need to inject it into patients.
This new technique could help treat people who suffer from non-Lymphoma, a rare form of lymphoma that causes more than 1,000 deaths every year.
And unlike the other types of cancer that are treated with chemotherapy and radiation, this rare form, called non-NHL, doesn’t grow.
Instead, it’s treated with an experimental drug called a synthetic protein.
This protein, which is chemically similar to the protein that’s produced by the body, binds to human proteins and kills them.
It’s similar to antibodies that the body uses to recognize and recognize its own cells.
In this way, the researchers found that it could kill non-HL cells.
And, like other antibodies, pepsteatin was able to bind to PEG proteins in mice.
The new treatment is the first to use pepsta to kill a tumor in a non-HFLL cell, which makes up less than 1 percent of the human population.
The team is working on a new form of the compound to be used in human trials.
If the drug works, the team hopes it could be applied to the first-ever clinical trial of its use in patients.
The research was funded by the National Institutes of Health.
For more on the non-HPLC cancer, watch: For more on non-HTLV-9, watch this: This story was produced by The Washington Post as part of the Marketplace partnership with The Investigative Fund.
